The weekly litigation news digest is live. Subscribe now

IP Verse

Cytokinetics competitive analysis

Loading summary...

Latest patents of Cytokinetics opposed by its competitors

Explore Cytokinetics's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 20, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP4370116
Jan 15, 2025Methods For Treating Hypertrophic Cardiomyopathy2
EP3999180
May 8, 2024Polymorphs Of (R)-N-(5-(5-Ethyl-1,2,4-Oxadiazol-3-Yl)-2,3-Dihydro-1H-Inden-1-Yl)-1-Methyl-1H-Pyrazole-4-Carboxamide1
EP2970123
Aug 14, 2019Salt Of Omecamtiv Mecarbil And Process For Preparing Salt1

Latest PTAB cases involving Cytokinetics

Discover the latest PTAB cases involving Cytokinetics, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Cytokinetics with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 20, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
CYTOKINETICS - 4 - -
GENERICS UK214 - - -
HAMM & WITTKOPP113 - - -
KELTIE22 - - -